Literature DB >> 11216956

Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy.

M Iwata1, T Yoshikawa, A Baba, T Anzai, H Mitamura, S Ogawa.   

Abstract

OBJECTIVES: We sought to define the clinical and long-term prognostic implications of autoantibodies that act against the second extracellular loop of beta1-adrenergic receptors (ARs) in patients with idiopathic dilated cardiomyopathy (IDC).
BACKGROUND: Although autoantibodies directed against various domains of beta-ARs are found in patients with IDC, only a subgroup against the second extracellular domain of beta1-ARs exerts intrinsic sympathomimetic-like actions on human beta-ARs. It is suggested that the autoantibodies take part in the pathophysiology of IDC and may affect long-term prognosis of patients with this disorder.
METHODS: Sera from 104 patients with IDC were screened for autoantibodies that act against the second extracellular loop of beta1-ARs by enzyme-linked immunosorbent assay, using a synthetic peptide corresponding to the domain. Relations of the autoantibodies to clinical variables and long-term prognosis were assessed by multivariate analysis.
RESULTS: Autoantibodies were detected in 40 patients (38%). Multifocal ventricular premature contractions (p < 0.01) and ventricular tachycardia (VT; p < 0.01) were more common in autoantibody-positive than in autoantibody-negative patients, although no differences in cardiac function or neurohormonal levels were demonstrated. The presence of autoantibodies (p = 0.001) and a low left ventricular ejection fraction (LVEF <30%; p = 0.02) were independent predictors of VT. Sudden death was independently predicted by the presence of autoantibodies (p = 0.03), as well as by LVEF <30% (p = 0.01), whereas total mortality was predicted only by LVEF <30% (p = 0.001).
CONCLUSIONS: Autoantibodies directed against the second extracellular loop of beta1-ARs were closely related to serious ventricular arrhythmias in patients with IDC, and the presence of autoantibodies independently predicted sudden death. These autoantibodies may contribute to electrical instability in patients with IDC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11216956     DOI: 10.1016/s0735-1097(00)01109-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  40 in total

Review 1.  The clinical significance of anti-beta-1 adrenergic receptor autoantibodies in cardiac disease.

Authors:  Udi Nussinovitch; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

2.  Antibodies with beta-adrenergic activity from chronic chagasic patients modulate the QT interval and M cell action potential duration.

Authors:  Emiliano Horacio Medei; José H M Nascimento; Roberto C Pedrosa; Luciane Barcellos; Masako O Masuda; Serge Sicouri; Marcelo V Elizari; Antonio C Campos de Carvalho
Journal:  Europace       Date:  2008-05-30       Impact factor: 5.214

Review 3.  Autoantibodies and cardiovascular dysfunction: cause or consequence?

Authors:  Yuji Nagatomo; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2014-12

4.  Down-regulation of microRNA-451a facilitates the activation and proliferation of CD4+ T cells by targeting Myc in patients with dilated cardiomyopathy.

Authors:  Zhipeng Zeng; Ke Wang; Yuanyuan Li; Ni Xia; Shaofang Nie; Bingjie Lv; Min Zhang; Xin Tu; Qianqian Li; Tingting Tang; Xiang Cheng
Journal:  J Biol Chem       Date:  2016-12-14       Impact factor: 5.157

Review 5.  Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases.

Authors:  Gerd Wallukat; Ingolf Schimke
Journal:  Semin Immunopathol       Date:  2014-04-29       Impact factor: 9.623

6.  Adoptive passive transfer of rabbit beta1-adrenoceptor peptide immune cardiomyopathy into the Rag2-/- mouse: participation of the ER stress.

Authors:  Jiahao Liu; Weike Mao; Chikao Iwai; Shuji Fukuoka; Raju Vulapalli; Huanlei Huang; Tingchung Wang; Virendra K Sharma; Shey-Shing Sheu; Michael Fu; Chang-Seng Liang
Journal:  J Mol Cell Cardiol       Date:  2007-11-24       Impact factor: 5.000

Review 7.  Recent insights into the role of autoimmunity in idiopathic dilated cardiomyopathy.

Authors:  Jason M Lappé; Clara M Pelfrey; W H Wilson Tang
Journal:  J Card Fail       Date:  2008-05-27       Impact factor: 5.712

8.  Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy.

Authors:  Roland Jahns; Valérie Boivin; Lutz Hein; Sven Triebel; Christiane E Angermann; Georg Ertl; Martin J Lohse
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

9.  Analysis of specific Th1/Th2 helper cell responses and IgG subtype antibodies in anti-CD4 monoclonal antibody treated mice with autoimmune cardiomyopathy.

Authors:  Zhaohui Wang; Yuhua Liao; Jing Yuan; Jinghui Zhang; Jihua Dong; Jinping Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-08-15

10.  Immunoadsorption therapy for patients with dilated cardiomyopathy and heart failure.

Authors:  Uichi Ikeda; Hiroki Kasai; Atsushi Izawa; Jun Koyama; Yoshikazu Yazaki; Masafumi Takahashi; Makoto Higuchi; Chang-Sung Koh; Keiji Yamamoto
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.